Drug‐drug interactions with candidate medications used for COVID‐19 treatment: An overview

Drug‐drug interaction (DDI) is a common clinical problem that has occurred as a result of the concomitant use of multiple drugs. DDI may occur in patients under treatment with medications used for coronavirus disease 2019 (COVID‐19; i.e., chloroquine, lopinavir/ritonavir, ribavirin, tocilizumab, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Rezaee, Haleh, Pourkarim, Fariba, Pourtaghi‐Anvarian, Samira, Entezari‐Maleki, Taher, Asvadi‐Kermani, Touraj, Nouri‐Vaskeh, Masoud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796804/
https://www.ncbi.nlm.nih.gov/pubmed/33421347
http://dx.doi.org/10.1002/prp2.705

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796804/
https://www.ncbi.nlm.nih.gov/pubmed/33421347
http://dx.doi.org/10.1002/prp2.705

Ejemplares similares